Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 3/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947911 | 0.94 | ITGB1 (0.46) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL2947907 | 0.94 | ITGB1 (0.46) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL2947915 | 0.94 | ITGB1 (0.46) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL2947906 | 0.94 | ITGB1 (0.46) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL20839967 | 0.91 | ITGB1 (0.42) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL24359843 | 0.88 | ITGB1 (0.57) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL11774604 | 0.88 | ITGB1 (0.57) | ITGB1ITGA4MAPTKDM4ETHRB | |
| SCHEMBL11774610 | 0.88 | ITGB1 (0.57) | ITGB1ITGA4MAPTKDM4ETHRB | |
| N-Monoacetylcystine SCHEMBL20816351 | 0.88 | MAPT (0.48) | ITGB1ITGA4MAPTKDM4ETHRB | |
| N-Monoacetylcystine SCHEMBL468824 | 0.88 | MAPT (0.48) | ITGB1ITGA4MAPTKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368072-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | NACUITY PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | claimed |
| US-20240342118-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | NACUITY PHARMACEUTICALS, INC. | 2024-10-17 | — | — | US | claimed |
| US-20230159448-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | NACUITY PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | claimed |
| US-11548851-B2 | Method for preparation of n-acetyl cysteine amide and derivatives thereof | NACUITY PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | claimed |
| US-20220024866-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | NACUITY PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| US-11091433-B2 | Method for preparation of N-acetyl cysteine amide and derivatives thereof | Nacuity Pharmaceutials, Inc. (US) | 2021-08-17 | — | — | US | claimed |
| US-20200277258-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | NACUITY PHARMACEUTICALS, INC. | 2020-09-03 | — | — | US | claimed |
| EP-3684756-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF | NaCuity Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | claimed |
| US-10590073-B2 | Method for preparation of N-acetyl cysteine amide and derivatives thereof | NACUITY PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | claimed |
| WO-2019060623-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF | NACUITY PHARMACEUTICALS, INC. (US) | 2019-03-28 | — | — | WO | claimed |
| US-20190084926-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | NACUITY PHARMACEUTICALS, INC. | 2019-03-21 | — | — | US | claimed |
| US-20250235416-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | NACUITY PHARMACEUTICALS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20240368072-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | NACUITY PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240368072-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | NACUITY PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240342118-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | NACUITY PHARMACEUTICALS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-10590073-B2 | Method for preparation of N-acetyl cysteine amide and derivatives thereof | NACUITY PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019060623-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF | NACUITY PHARMACEUTICALS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019060623-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE AND DERIVATIVES THEREOF | NACUITY PHARMACEUTICALS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
| US-20190084926-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | NACUITY PHARMACEUTICALS, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20190084926-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | NACUITY PHARMACEUTICALS, INC. | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548851-B2 | Method for preparation of n-acetyl cysteine amide and derivatives thereof | AADAC, GCLC, DDC | ITGB1 4098/4885ITGA4 3626/4885MAPT 4148/4885 |
| US-20220024866-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | AADAC, GCLC, DDC | ITGB1 4098/4885ITGA4 3626/4885MAPT 4148/4885 |
| US-20200277258-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | AADAC, GCLC, DDC | ITGB1 4098/4885ITGA4 3626/4885MAPT 4148/4885 |
| US-10590073-B2 | Method for preparation of N-acetyl cysteine amide and derivatives thereof | CTH, AHCY, AADAT | ITGB1 4539/4885ITGA4 3215/4885MAPT 2992/4885 |
| US-20250235416-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE, DERIVATIVES AND TABLETS THEREOF | NACA, NAA15, SLC33A1 | ITGB1 517/4885ITGA4 257/4885MAPT 647/4885 |
| US-20190084926-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | CTH, AHCY, AADAT | ITGB1 4539/4885ITGA4 3215/4885MAPT 2992/4885 |
| US-11091433-B2 | Method for preparation of N-acetyl cysteine amide and derivatives thereof | AADAC, GCLC, DDC | ITGB1 4098/4885ITGA4 3626/4885MAPT 4148/4885 |
| US-20230159448-A1 | Method for Preparation of N-Acetyl Cysteine Amide and Derivatives Thereof | AADAC, GCLC, DDC | ITGB1 4330/4885ITGA4 3804/4885MAPT 4279/4885 |
| US-20240342118-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | NAAA, AADAC, NAT1 | ITGB1 3466/4885ITGA4 4069/4885MAPT 3991/4885 |
| US-20240368072-A1 | METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES | NAAA, AADAC, NAT1 | ITGB1 3466/4885ITGA4 4069/4885MAPT 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.